INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreement with Uniphar

The Medical News ·
Health & Medicine United Kingdom

INmune Bio Inc. (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for…

Read original article on The Medical News →

Related news